Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is intend to explore the efficacy and safety of combined treatment of camrelizumab
and bevacizumab in adult patients with recurrent glioblastoma.